Skip to content
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • U.S. Psychedelic Policy Reform
    • Worldwide Psychedelic Laws
    • Oregon Psilocybin Services Tracker
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Menu
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • U.S. Psychedelic Policy Reform
    • Worldwide Psychedelic Laws
    • Oregon Psilocybin Services Tracker
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Subscribe
Search
Close this search box.
Read more about the article Filament Announces First GMP Batch of Pharmaceutical Grade Natural Psilocybin

Filament Announces First GMP Batch of Pharmaceutical Grade Natural Psilocybin

  • Post published:June 11, 2021
  • Post category:Press Release
Read more about the article Filament Cultivates 20th Psychedelic Mushroom Variety and Provides Propagation Update

Filament Cultivates 20th Psychedelic Mushroom Variety and Provides Propagation Update

  • Post published:June 9, 2021
  • Post category:Press Release
Read more about the article Filament Health Partners with TrPR Psychedelic Research Program at UCSF to Advance First Drug Candidates Through FDA Phase 1 and Phase 2 Clinical Trials

Filament Health Partners with TrPR Psychedelic Research Program at UCSF to Advance First Drug Candidates Through FDA Phase 1 and Phase 2 Clinical Trials

  • Post published:May 31, 2021
  • Post category:Press Release
Read more about the article Filament Announces C$10M Offering and Filing of Initial Listing Application

Filament Announces C$10M Offering and Filing of Initial Listing Application

  • Post published:May 17, 2021
  • Post category:Press Release

End of content

No more pages to load

← Newer Posts

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More